ID   GLCNE_HUMAN             Reviewed;         722 AA.
AC   Q9Y223; A6PZH2; A6PZH3; A7UNU7; B2R6E1; B7Z372; B7Z428; D3DRP7;
AC   F5H499; H0YFA7; Q0VA94;
DT   15-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   15-MAR-2017, entry version 149.
DE   RecName: Full=Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase;
DE   AltName: Full=UDP-GlcNAc-2-epimerase/ManAc kinase;
DE   Includes:
DE     RecName: Full=UDP-N-acetylglucosamine 2-epimerase (hydrolyzing);
DE              EC=3.2.1.183;
DE     AltName: Full=UDP-GlcNAc-2-epimerase;
DE     AltName: Full=Uridine diphosphate-N-acetylglucosamine-2-epimerase;
DE   Includes:
DE     RecName: Full=N-acetylmannosamine kinase;
DE              EC=2.7.1.60;
DE     AltName: Full=ManAc kinase;
GN   Name=GNE; Synonyms=GLCNE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=10431835; DOI=10.1016/S0014-5793(99)00837-6;
RA   Lucka L., Krause M., Danker K., Reutter W., Horstkorte R.;
RT   "Primary structure and expression analysis of human UDP-N-acetyl-
RT   glucosamine-2-epimerase/N-acetylmannosamine kinase, the bifunctional
RT   enzyme in neuraminic acid biosynthesis.";
RL   FEBS Lett. 454:341-344(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANTS SIALURIA LEU-263; GLN-266 AND TRP-266.
RX   PubMed=10330343; DOI=10.1086/302411;
RA   Seppala R., Lehto V.-P., Gahl W.A.;
RT   "Mutations in the human UDP-N-acetylglucosamine 2-epimerase gene
RT   define the disease sialuria and the allosteric site of the enzyme.";
RL   Am. J. Hum. Genet. 64:1563-1569(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Small intestine;
RA   Wang S.S., Ryll T.;
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RA   Huizing M., Anikster Y., Gahl W.A.;
RT   "Organization of the human UDP-N-acetylglucosamine 2-epimerase gene
RT   and characterization of a related pseudogene; relevance for mutation
RT   detection in patients with sialuria.";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RA   Pramono Z.A.D., Lai P.S., Seah I.A.L., Ong B., Yee W.C.;
RT   "mRNA analysis revealed splice mutation and expression alteration of
RT   GNE gene in distal myopathy with rimmed vacuoles (DMRV) patients.";
RL   Submitted (AUG-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 5), AND
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 24-694 (ISOFORM 3).
RC   TISSUE=Hippocampus, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   37-694 (ISOFORM 3), AND TISSUE SPECIFICITY.
RX   PubMed=17597614; DOI=10.1016/j.febslet.2007.06.026;
RA   Reinke S.O., Hinderlich S.;
RT   "Prediction of three different isoforms of the human UDP-N-
RT   acetylglucosamine 2-epimerase/N-acetylmannosamine kinase.";
RL   FEBS Lett. 581:3327-3331(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   ENZYME REGULATION, AND INVOLVEMENT IN SIALURIA.
RX   PubMed=2808337;
RA   Weiss P., Tietze F., Gahl W.A., Seppala R., Ashwell G.;
RT   "Identification of the metabolic defect in sialuria.";
RL   J. Biol. Chem. 264:17635-17636(1989).
RN   [12]
RP   FUNCTION.
RX   PubMed=10334995; DOI=10.1126/science.284.5418.1372;
RA   Keppler O.T., Hinderlich S., Langner J., Schwartz-Albiez R.,
RA   Reutter W., Pawlita M.;
RT   "UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation.";
RL   Science 284:1372-1376(1999).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.84 ANGSTROMS) OF 406-720, AND SUBUNIT.
RX   PubMed=19841673; DOI=10.1371/journal.pone.0007165;
RA   Tong Y., Tempel W., Nedyalkova L., Mackenzie F., Park H.W.;
RT   "Crystal structure of the N-acetylmannosamine kinase domain of GNE.";
RL   PLoS ONE 4:E7165-E7165(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.64 ANGSTROMS) OF 406-720 IN COMPLEX WITH ADP
RP   AND N-ACETYLMANNOSAMINE, ZINC-BINDING SITES, ACTIVE SITE, AND SUBUNIT.
RX   PubMed=22343627; DOI=10.1074/jbc.M111.318170;
RA   Martinez J., Nguyen L.D., Hinderlich S., Zimmer R., Tauberger E.,
RA   Reutter W., Saenger W., Fan H., Moniot S.;
RT   "Crystal structures of N-acetylmannosamine kinase provide insights
RT   into enzyme activity and inhibition.";
RL   J. Biol. Chem. 287:13656-13665(2012).
RN   [17]
RP   VARIANT SIALURIA GLN-266.
RX   PubMed=10356312; DOI=10.1006/mgme.1999.2852;
RA   Ferreira H., Seppala R., Pinto R., Huizing M., Martins E., Braga A.C.,
RA   Gomes L., Krasnewich D.M., Sa Miranda M.C., Gahl W.A.;
RT   "Sialuria in a Portuguese girl: clinical, biochemical, and molecular
RT   characteristics.";
RL   Mol. Genet. Metab. 67:131-137(1999).
RN   [18]
RP   CHARACTERIZATION OF VARIANT SIALURIA GLN-266.
RX   PubMed=11326336; DOI=10.1086/320598;
RA   Leroy J.G., Seppala R., Huizing M., Dacremont G., De Simpel H.,
RA   Van Coster R.N., Orvisky E., Krasnewich D.M., Gahl W.A.;
RT   "Dominant inheritance of sialuria, an inborn error of feedback
RT   inhibition.";
RL   Am. J. Hum. Genet. 68:1419-1427(2001).
RN   [19]
RP   VARIANTS NM ASN-225; GLN-246; GLU-576; THR-631; MET-696 AND THR-712.
RX   PubMed=11528398; DOI=10.1038/ng718;
RA   Eisenberg I., Avidan N., Potikha T., Hochner H., Chen M., Olender T.,
RA   Barash M., Shemesh M., Sadeh M., Grabov-Nardini G., Shmilevich I.,
RA   Friedmann A., Karpati G., Bradley W.G., Baumbach L., Lancet D.,
RA   Asher E.B., Beckmann J.S., Argov Z., Mitrani-Rosenbaum S.;
RT   "The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase
RT   gene is mutated in recessive hereditary inclusion body myopathy.";
RL   Nat. Genet. 29:83-87(2001).
RN   [20]
RP   VARIANT NM LEU-572.
RX   PubMed=12325084; DOI=10.1002/ana.10341;
RA   Arai A., Tanaka K., Ikeuchi T., Igarashi S., Kobayashi H., Asaka T.,
RA   Date H., Saito M., Tanaka H., Kawasaki S., Uyama E., Mizusawa H.,
RA   Fukuhara N., Tsuji S.;
RT   "A novel mutation in the GNE gene and a linkage disequilibrium in
RT   Japanese pedigrees.";
RL   Ann. Neurol. 52:516-519(2002).
RN   [21]
RP   VARIANTS NM VAL-460 AND LEU-572.
RX   PubMed=11916006; DOI=10.1007/s100380200004;
RA   Kayashima T., Matsuo H., Satoh A., Ohta T., Yoshiura K., Matsumoto N.,
RA   Nakane Y., Niikawa N., Kishino T.;
RT   "Nonaka myopathy is caused by mutations in the UDP-N-
RT   acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE).";
RL   J. Hum. Genet. 47:77-79(2002).
RN   [22]
RP   VARIANTS NM ASN-225; GLN-246; TRP-246; VAL-460; VAL-524; LEU-572;
RP   GLU-576; THR-631; HIS-675; MET-696 AND THR-712.
RX   PubMed=12409274; DOI=10.1016/S1096-7192(02)00141-5;
RA   Darvish D., Vahedifar P., Huo Y.;
RT   "Four novel mutations associated with autosomal recessive inclusion
RT   body myopathy (MIM: 600737).";
RL   Mol. Genet. Metab. 77:252-256(2002).
RN   [23]
RP   VARIANTS NM LEU-572 AND VAL-631.
RX   PubMed=12177386; DOI=10.1212/WNL.59.3.451;
RA   Tomimitsu H., Ishikawa K., Shimizu J., Ohkoshi N., Kanazawa I.,
RA   Mizusawa H.;
RT   "Distal myopathy with rimmed vacuoles: novel mutations in the GNE
RT   gene.";
RL   Neurology 59:451-454(2002).
RN   [24]
RP   VARIANTS NM GLN-132; VAL-176; CYS-177; GLN-306; ALA-331; TYR-378;
RP   THR-472; LEU-572; THR-630 AND VAL-631.
RX   PubMed=12473753; DOI=10.1212/01.WNL.0000041631.28557.C6;
RA   Nishino I., Noguchi S., Murayama K., Driss A., Sugie K., Oya Y.,
RA   Nagata T., Chida K., Takahashi T., Takusa Y., Ohi T., Nishimiya J.,
RA   Sunohara N., Ciafaloni E., Kawai M., Aoki M., Nonaka I.;
RT   "Distal myopathy with rimmed vacuoles is allelic to hereditary
RT   inclusion body myopathy.";
RL   Neurology 59:1689-1693(2002).
RN   [25]
RP   VARIANTS NM ALA-216 AND VAL-631.
RX   PubMed=12473769; DOI=10.1212/01.WNL.0000039780.13681.AD;
RA   Vasconcelos O.M., Raju R., Dalakas M.C.;
RT   "GNE mutations in an American family with quadriceps-sparing IBM and
RT   lack of mutations in s-IBM.";
RL   Neurology 59:1776-1779(2002).
RN   [26]
RP   VARIANTS NM VAL-171 AND THR-712.
RX   PubMed=12473780; DOI=10.1212/01.WNL.0000031808.04545.E0;
RA   Broccolini A., Pescatori M., D'Amico A., Sabino A., Silvestri G.,
RA   Ricci E., Servidei S., Tonali P.A., Mirabella M.;
RT   "An Italian family with autosomal recessive inclusion-body myopathy
RT   and mutations in the GNE gene.";
RL   Neurology 59:1808-1809(2002).
RN   [27]
RP   VARIANTS NM LEU-36; PHE-200; ASN-225; GLN-246; VAL-303; TYR-378;
RP   VAL-460; CYS-528; THR-557; LEU-572; GLU-576; THR-587; THR-631;
RP   VAL-631; MET-696 AND THR-712.
RX   PubMed=12497639; DOI=10.1002/humu.9100;
RA   Eisenberg I., Grabov-Nardini G., Hochner H., Korner M., Sadeh M.,
RA   Bertorini T., Bushby K., Castellan C., Felice K., Mendell J.,
RA   Merlini L., Shilling C., Wirguin I., Argov Z., Mitrani-Rosenbaum S.;
RT   "Mutations spectrum of GNE in hereditary inclusion body myopathy
RT   sparing the quadriceps.";
RL   Hum. Mutat. 21:99-99(2003).
RN   [28]
RP   VARIANT NM CYS-162.
RX   PubMed=12811782; DOI=10.1002/mus.10391;
RA   Del Bo R., Baron P., Prelle A., Serafini M., Moggio M., Di Fonzo A.,
RA   Castagni M., Bresolin N., Comi G.P.;
RT   "Novel missense mutation and large deletion of GNE gene in autosomal-
RT   recessive inclusion-body myopathy.";
RL   Muscle Nerve 28:113-117(2003).
RN   [29]
RP   VARIANTS NM THR-472 AND LEU-572.
RX   PubMed=12913203; DOI=10.1212/01.WNL.0000061520.63546.8F;
RA   Yabe I., Higashi T., Kikuchi S., Sasaki H., Fukazawa T., Yoshida K.,
RA   Tashiro K.;
RT   "GNE mutations causing distal myopathy with rimmed vacuoles with
RT   inflammation.";
RL   Neurology 61:384-386(2003).
RN   [30]
RP   VARIANTS NM SER-27; SER-206; GLN-246; SER-519 AND THR-600.
RX   PubMed=15146476; DOI=10.1002/humu.9252;
RA   Broccolini A., Ricci E., Cassandrini D., Gliubizzi C., Bruno C.,
RA   Tonoli E., Silvestri G., Pescatori M., Rodolico C., Sinicropi S.,
RA   Servidei S., Zara F., Minetti C., Tonali P.A., Mirabella M.;
RT   "Novel GNE mutations in Italian families with autosomal recessive
RT   hereditary inclusion-body myopathy.";
RL   Hum. Mutat. 23:632-632(2004).
CC   -!- FUNCTION: Regulates and initiates biosynthesis of N-
CC       acetylneuraminic acid (NeuAc), a precursor of sialic acids. Plays
CC       an essential role in early development (By similarity). Required
CC       for normal sialylation in hematopoietic cells. Sialylation is
CC       implicated in cell adhesion, signal transduction, tumorigenicity
CC       and metastatic behavior of malignant cells. {ECO:0000250,
CC       ECO:0000269|PubMed:10334995}.
CC   -!- CATALYTIC ACTIVITY: UDP-N-acetyl-alpha-D-glucosamine + H(2)O = N-
CC       acetyl-D-mannosamine + UDP.
CC   -!- CATALYTIC ACTIVITY: ATP + N-acyl-D-mannosamine = ADP + N-acyl-D-
CC       mannosamine 6-phosphate.
CC   -!- ENZYME REGULATION: Allosterically regulated (Probable); feedback
CC       inhibited by cytidine monophosphate-N-acetylneuraminic acid (CMP-
CC       Neu5Ac), the end product of neuraminic acid biosynthesis. Activity
CC       is dependent on oligomerization. The monomer is inactive, whereas
CC       the dimer catalyzes only the phosphorylation of N-
CC       acetylmannosamine; the hexamer is fully active for both enzyme
CC       activities (By similarity). Up-regulated after PKC-dependent
CC       phosphorylation. {ECO:0000250, ECO:0000269|PubMed:2808337}.
CC   -!- PATHWAY: Amino-sugar metabolism; N-acetylneuraminate biosynthesis.
CC   -!- SUBUNIT: Homodimer and homohexamer. {ECO:0000269|PubMed:19841673,
CC       ECO:0000269|PubMed:22343627}.
CC   -!- INTERACTION:
CC       Q6UY14-3:ADAMTSL4; NbExp=3; IntAct=EBI-4291090, EBI-10173507;
CC       Q969Y2:GTPBP3; NbExp=3; IntAct=EBI-4291090, EBI-740290;
CC       Q15323:KRT31; NbExp=3; IntAct=EBI-4291090, EBI-948001;
CC       P60370:KRTAP10-5; NbExp=3; IntAct=EBI-4291090, EBI-10172150;
CC       P60409:KRTAP10-7; NbExp=3; IntAct=EBI-4291090, EBI-10172290;
CC       P60410:KRTAP10-8; NbExp=3; IntAct=EBI-4291090, EBI-10171774;
CC       P60411:KRTAP10-9; NbExp=3; IntAct=EBI-4291090, EBI-10172052;
CC       Q9BQ66:KRTAP4-12; NbExp=3; IntAct=EBI-4291090, EBI-739863;
CC       P26371:KRTAP5-9; NbExp=3; IntAct=EBI-4291090, EBI-3958099;
CC       Q9BYQ4:KRTAP9-2; NbExp=3; IntAct=EBI-4291090, EBI-1044640;
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-4291090, EBI-945833;
CC       O43597:SPRY2; NbExp=3; IntAct=EBI-4291090, EBI-742487;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=GNE1;
CC         IsoId=Q9Y223-1; Sequence=Displayed;
CC       Name=2; Synonyms=GNE2;
CC         IsoId=Q9Y223-2; Sequence=VSP_041027;
CC       Name=3; Synonyms=GNE3;
CC         IsoId=Q9Y223-3; Sequence=VSP_041028;
CC       Name=4;
CC         IsoId=Q9Y223-4; Sequence=VSP_043474;
CC       Name=5;
CC         IsoId=Q9Y223-5; Sequence=VSP_043975, VSP_043976;
CC   -!- TISSUE SPECIFICITY: Highest expression in liver and placenta. Also
CC       found in heart, brain, lung, kidney, skeletal muscle and pancreas.
CC       Isoform 1 is expressed in heart, brain, kidney, liver, placenta,
CC       lung, spleen, pancreas, skeletal muscle and colon. Isoform 2 is
CC       expressed mainly in placenta, but also in brain, kidney, liver,
CC       lung, pancreas and colon. Isoform 3 is expressed at low level in
CC       kidney, liver, placenta and colon. {ECO:0000269|PubMed:10330343,
CC       ECO:0000269|PubMed:10431835, ECO:0000269|PubMed:17597614}.
CC   -!- PTM: Phosphorylated by PKC. {ECO:0000250}.
CC   -!- DISEASE: Sialuria (SIALURIA) [MIM:269921]: In sialuria, free
CC       sialic acid accumulates in the cytoplasm and gram quantities of
CC       neuraminic acid are secreted in the urine. The metabolic defect
CC       involves lack of feedback inhibition of UDP-GlcNAc 2-epimerase by
CC       CMP-Neu5Ac, resulting in constitutive overproduction of free
CC       Neu5Ac. Clinical features include variable degrees of
CC       developmental delay, coarse facial features and hepatomegaly.
CC       Sialuria inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:10330343, ECO:0000269|PubMed:10356312,
CC       ECO:0000269|PubMed:11326336, ECO:0000269|PubMed:2808337}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Nonaka myopathy (NM) [MIM:605820]: Autosomal recessive
CC       muscular disorder, allelic to inclusion body myopathy 2. It is
CC       characterized by weakness of the anterior compartment of the lower
CC       limbs with onset in early adulthood, and sparing of the quadriceps
CC       muscles. As the inclusion body myopathy, NM is histologically
CC       characterized by the presence of numerous rimmed vacuoles without
CC       inflammatory changes in muscle specimens.
CC       {ECO:0000269|PubMed:11528398, ECO:0000269|PubMed:11916006,
CC       ECO:0000269|PubMed:12177386, ECO:0000269|PubMed:12325084,
CC       ECO:0000269|PubMed:12409274, ECO:0000269|PubMed:12473753,
CC       ECO:0000269|PubMed:12473769, ECO:0000269|PubMed:12473780,
CC       ECO:0000269|PubMed:12497639, ECO:0000269|PubMed:12811782,
CC       ECO:0000269|PubMed:12913203, ECO:0000269|PubMed:15146476}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the UDP-N-
CC       acetylglucosamine 2-epimerase family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the ROK
CC       (NagC/XylR) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAH12414.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ238764; CAB42607.1; -; mRNA.
DR   EMBL; AF051852; AAD32251.1; -; mRNA.
DR   EMBL; AF155663; AAD38197.1; -; mRNA.
DR   EMBL; AF317635; AAG31661.1; -; Genomic_DNA.
DR   EMBL; EU093084; ABU55403.1; -; mRNA.
DR   EMBL; AK295562; BAH12108.1; -; mRNA.
DR   EMBL; AK296687; BAH12414.1; ALT_INIT; mRNA.
DR   EMBL; AK312539; BAG35438.1; -; mRNA.
DR   EMBL; AM697708; CAM91424.1; -; mRNA.
DR   EMBL; AM697709; CAM91425.1; -; mRNA.
DR   EMBL; AL158830; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58307.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58309.1; -; Genomic_DNA.
DR   EMBL; BC121179; AAI21180.1; -; mRNA.
DR   CCDS; CCDS47965.1; -. [Q9Y223-2]
DR   CCDS; CCDS55308.1; -. [Q9Y223-5]
DR   CCDS; CCDS55309.1; -. [Q9Y223-4]
DR   CCDS; CCDS55310.1; -. [Q9Y223-3]
DR   CCDS; CCDS6602.1; -. [Q9Y223-1]
DR   RefSeq; NP_001121699.1; NM_001128227.2. [Q9Y223-2]
DR   RefSeq; NP_001177312.1; NM_001190383.1. [Q9Y223-4]
DR   RefSeq; NP_001177313.1; NM_001190384.1. [Q9Y223-5]
DR   RefSeq; NP_001177317.1; NM_001190388.1. [Q9Y223-3]
DR   RefSeq; NP_005467.1; NM_005476.5. [Q9Y223-1]
DR   RefSeq; XP_016869656.1; XM_017014167.1. [Q9Y223-1]
DR   UniGene; Hs.5920; -.
DR   PDB; 2YHW; X-ray; 1.64 A; A=406-720.
DR   PDB; 2YHY; X-ray; 1.82 A; A=406-720.
DR   PDB; 2YI1; X-ray; 2.15 A; A=406-720.
DR   PDB; 3EO3; X-ray; 2.84 A; A/B/C=406-720.
DR   PDB; 4ZHT; X-ray; 2.69 A; A/B/C/D=1-405.
DR   PDBsum; 2YHW; -.
DR   PDBsum; 2YHY; -.
DR   PDBsum; 2YI1; -.
DR   PDBsum; 3EO3; -.
DR   PDBsum; 4ZHT; -.
DR   ProteinModelPortal; Q9Y223; -.
DR   SMR; Q9Y223; -.
DR   BioGrid; 115337; 27.
DR   IntAct; Q9Y223; 52.
DR   STRING; 9606.ENSP00000379839; -.
DR   iPTMnet; Q9Y223; -.
DR   PhosphoSitePlus; Q9Y223; -.
DR   BioMuta; GNE; -.
DR   DMDM; 45476991; -.
DR   EPD; Q9Y223; -.
DR   PaxDb; Q9Y223; -.
DR   PeptideAtlas; Q9Y223; -.
DR   PRIDE; Q9Y223; -.
DR   DNASU; 10020; -.
DR   Ensembl; ENST00000377902; ENSP00000367134; ENSG00000159921. [Q9Y223-1]
DR   Ensembl; ENST00000396594; ENSP00000379839; ENSG00000159921. [Q9Y223-2]
DR   Ensembl; ENST00000447283; ENSP00000414760; ENSG00000159921. [Q9Y223-4]
DR   Ensembl; ENST00000539208; ENSP00000445117; ENSG00000159921. [Q9Y223-5]
DR   Ensembl; ENST00000539815; ENSP00000439155; ENSG00000159921. [Q9Y223-1]
DR   Ensembl; ENST00000543356; ENSP00000437765; ENSG00000159921. [Q9Y223-3]
DR   GeneID; 10020; -.
DR   KEGG; hsa:10020; -.
DR   UCSC; uc010mlg.5; human. [Q9Y223-1]
DR   CTD; 10020; -.
DR   DisGeNET; 10020; -.
DR   GeneCards; GNE; -.
DR   GeneReviews; GNE; -.
DR   HGNC; HGNC:23657; GNE.
DR   HPA; HPA007045; -.
DR   HPA; HPA027258; -.
DR   MalaCards; GNE; -.
DR   MIM; 269921; phenotype.
DR   MIM; 600737; phenotype.
DR   MIM; 603824; gene.
DR   MIM; 605820; phenotype.
DR   neXtProt; NX_Q9Y223; -.
DR   OpenTargets; ENSG00000159921; -.
DR   Orphanet; 602; Distal myopathy, Nonaka type.
DR   Orphanet; 3166; Sialuria.
DR   PharmGKB; PA134987566; -.
DR   eggNOG; ENOG410IE3W; Eukaryota.
DR   eggNOG; COG0381; LUCA.
DR   eggNOG; COG1940; LUCA.
DR   GeneTree; ENSGT00390000017246; -.
DR   HOGENOM; HOG000008254; -.
DR   HOVERGEN; HBG051733; -.
DR   InParanoid; Q9Y223; -.
DR   KO; K12409; -.
DR   OMA; IAMCEDH; -.
DR   OrthoDB; EOG091G025K; -.
DR   PhylomeDB; Q9Y223; -.
DR   TreeFam; TF332239; -.
DR   BRENDA; 2.7.1.60; 2681.
DR   BRENDA; 3.2.1.183; 2681.
DR   BRENDA; 5.1.3.14; 2681.
DR   Reactome; R-HSA-4085001; Sialic acid metabolism.
DR   UniPathway; UPA00630; -.
DR   ChiTaRS; GNE; human.
DR   EvolutionaryTrace; Q9Y223; -.
DR   GeneWiki; GNE_(gene); -.
DR   GenomeRNAi; 10020; -.
DR   PRO; PR:Q9Y223; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000159921; -.
DR   CleanEx; HS_GNE; -.
DR   Genevisible; Q9Y223; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004553; F:hydrolase activity, hydrolyzing O-glycosyl compounds; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0009384; F:N-acylmannosamine kinase activity; TAS:Reactome.
DR   GO; GO:0008761; F:UDP-N-acetylglucosamine 2-epimerase activity; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0006045; P:N-acetylglucosamine biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006054; P:N-acetylneuraminate metabolic process; TAS:ProtInc.
DR   GO; GO:0006047; P:UDP-N-acetylglucosamine metabolic process; IEA:InterPro.
DR   CDD; cd03786; GT1_UDP-GlcNAc_2-Epimerase; 1.
DR   InterPro; IPR000600; ROK.
DR   InterPro; IPR020004; UDP-GlcNAc_Epase.
DR   InterPro; IPR003331; UDP_GlcNAc_Epimerase_2_dom.
DR   PANTHER; PTHR18964; PTHR18964; 1.
DR   Pfam; PF02350; Epimerase_2; 1.
DR   Pfam; PF00480; ROK; 1.
DR   TIGRFAMs; TIGR03568; NeuC_NnaA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Disease mutation; Hydrolase; Kinase;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Transferase; Zinc.
FT   CHAIN         1    722       Bifunctional UDP-N-acetylglucosamine 2-
FT                                epimerase/N-acetylmannosamine kinase.
FT                                /FTId=PRO_0000095716.
FT   NP_BIND     411    420       ATP.
FT   NP_BIND     543    552       ATP.
FT   REGION        1      ?       UDP-N-acetylglucosamine 2-epimerase.
FT   REGION      406    722       N-acetylmannosamine kinase.
FT   ACT_SITE    517    517       {ECO:0000269|PubMed:22343627}.
FT   METAL       569    569       Zinc.
FT   METAL       579    579       Zinc.
FT   METAL       581    581       Zinc.
FT   METAL       586    586       Zinc.
FT   BINDING     477    477       Substrate.
FT   BINDING     489    489       Substrate.
FT   BINDING     517    517       Substrate.
FT   BINDING     566    566       Substrate.
FT   BINDING     569    569       Substrate.
FT   BINDING     588    588       Substrate.
FT   VAR_SEQ       1     59       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043975.
FT   VAR_SEQ       1     55       MEKNGNNRKLRVCVATCNRADYSKLAPIMFGIKTEPEFFEL
FT                                DVVVLGSHLIDDYG -> MPIGDCSVAAKPRKQLLCSLFQT
FT                                TLGYRARASGWKPMVICRGSHAFKDLI (in isoform
FT                                3). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:17597614}.
FT                                /FTId=VSP_041028.
FT   VAR_SEQ       1      1       M -> METYGYLQRESCFQGPHELYFKNLSKRNKQIM (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:17597614}.
FT                                /FTId=VSP_041027.
FT   VAR_SEQ     206    256       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043976.
FT   VAR_SEQ     471    544       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_043474.
FT   VARIANT      27     27       P -> S (in NM).
FT                                {ECO:0000269|PubMed:15146476}.
FT                                /FTId=VAR_021771.
FT   VARIANT      36     36       P -> L (in NM).
FT                                {ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017945.
FT   VARIANT     132    132       H -> Q (in NM).
FT                                {ECO:0000269|PubMed:12473753}.
FT                                /FTId=VAR_021772.
FT   VARIANT     162    162       R -> C (in NM; dbSNP:rs769215411).
FT                                {ECO:0000269|PubMed:12811782}.
FT                                /FTId=VAR_021773.
FT   VARIANT     171    171       M -> V (in NM; dbSNP:rs121908634).
FT                                {ECO:0000269|PubMed:12473780}.
FT                                /FTId=VAR_021774.
FT   VARIANT     176    176       D -> V (in NM; dbSNP:rs139425890).
FT                                {ECO:0000269|PubMed:12473753}.
FT                                /FTId=VAR_021775.
FT   VARIANT     177    177       R -> C (in NM; dbSNP:rs539332585).
FT                                {ECO:0000269|PubMed:12473753}.
FT                                /FTId=VAR_021776.
FT   VARIANT     200    200       I -> F (in NM; dbSNP:rs369328625).
FT                                {ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017946.
FT   VARIANT     206    206       G -> S (in NM; moderate phenotype with
FT                                unusual involvement of quadriceps;
FT                                dbSNP:rs766266918).
FT                                {ECO:0000269|PubMed:15146476}.
FT                                /FTId=VAR_021777.
FT   VARIANT     216    216       V -> A (in NM; dbSNP:rs779694939).
FT                                {ECO:0000269|PubMed:12473769}.
FT                                /FTId=VAR_021778.
FT   VARIANT     225    225       D -> N (in NM; dbSNP:rs121908630).
FT                                {ECO:0000269|PubMed:11528398,
FT                                ECO:0000269|PubMed:12409274,
FT                                ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017947.
FT   VARIANT     246    246       R -> Q (in NM; dbSNP:rs121908629).
FT                                {ECO:0000269|PubMed:11528398,
FT                                ECO:0000269|PubMed:12409274,
FT                                ECO:0000269|PubMed:12497639,
FT                                ECO:0000269|PubMed:15146476}.
FT                                /FTId=VAR_017948.
FT   VARIANT     246    246       R -> W (in NM; dbSNP:rs773729410).
FT                                {ECO:0000269|PubMed:12409274}.
FT                                /FTId=VAR_017949.
FT   VARIANT     263    263       R -> L (in SIALURIA; strong reduction of
FT                                feedback inhibition by CMP-Neu5Ac;
FT                                dbSNP:rs121908623).
FT                                {ECO:0000269|PubMed:10330343}.
FT                                /FTId=VAR_017950.
FT   VARIANT     266    266       R -> Q (in SIALURIA; abolishes feedback
FT                                inhibition by CMP-Neu5Ac;
FT                                dbSNP:rs121908622).
FT                                {ECO:0000269|PubMed:10330343,
FT                                ECO:0000269|PubMed:10356312,
FT                                ECO:0000269|PubMed:11326336}.
FT                                /FTId=VAR_017951.
FT   VARIANT     266    266       R -> W (in sialuria; dbSNP:rs121908621).
FT                                {ECO:0000269|PubMed:10330343}.
FT                                /FTId=VAR_017952.
FT   VARIANT     303    303       C -> V (in NM; requires 2 nucleotide
FT                                substitutions; dbSNP:rs121908633).
FT                                {ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017953.
FT   VARIANT     306    306       R -> Q (in NM).
FT                                {ECO:0000269|PubMed:12473753}.
FT                                /FTId=VAR_021779.
FT   VARIANT     331    331       V -> A (in NM).
FT                                {ECO:0000269|PubMed:12473753}.
FT                                /FTId=VAR_021780.
FT   VARIANT     378    378       D -> Y (in NM; dbSNP:rs199877522).
FT                                {ECO:0000269|PubMed:12473753,
FT                                ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017954.
FT   VARIANT     460    460       A -> V (in NM; dbSNP:rs121908631).
FT                                {ECO:0000269|PubMed:11916006,
FT                                ECO:0000269|PubMed:12409274,
FT                                ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017955.
FT   VARIANT     472    472       I -> T (in NM).
FT                                {ECO:0000269|PubMed:12473753,
FT                                ECO:0000269|PubMed:12913203}.
FT                                /FTId=VAR_021781.
FT   VARIANT     519    519       N -> S (in NM).
FT                                {ECO:0000269|PubMed:15146476}.
FT                                /FTId=VAR_021782.
FT   VARIANT     524    524       A -> V (in NM; dbSNP:rs764698870).
FT                                {ECO:0000269|PubMed:12409274}.
FT                                /FTId=VAR_017956.
FT   VARIANT     528    528       F -> C (in NM).
FT                                {ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017957.
FT   VARIANT     557    557       I -> T (in NM).
FT                                {ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017958.
FT   VARIANT     572    572       V -> L (in NM; dbSNP:rs121908632).
FT                                {ECO:0000269|PubMed:11916006,
FT                                ECO:0000269|PubMed:12177386,
FT                                ECO:0000269|PubMed:12325084,
FT                                ECO:0000269|PubMed:12409274,
FT                                ECO:0000269|PubMed:12473753,
FT                                ECO:0000269|PubMed:12497639,
FT                                ECO:0000269|PubMed:12913203}.
FT                                /FTId=VAR_017959.
FT   VARIANT     576    576       G -> E (in NM; dbSNP:rs121908625).
FT                                {ECO:0000269|PubMed:11528398,
FT                                ECO:0000269|PubMed:12409274,
FT                                ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017960.
FT   VARIANT     587    587       I -> T (in NM; dbSNP:rs748949603).
FT                                {ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017961.
FT   VARIANT     600    600       A -> T (in NM; dbSNP:rs387906347).
FT                                {ECO:0000269|PubMed:15146476}.
FT                                /FTId=VAR_021783.
FT   VARIANT     630    630       A -> T (in NM).
FT                                {ECO:0000269|PubMed:12473753}.
FT                                /FTId=VAR_021784.
FT   VARIANT     631    631       A -> T (in NM; dbSNP:rs121908626).
FT                                {ECO:0000269|PubMed:11528398,
FT                                ECO:0000269|PubMed:12409274,
FT                                ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017962.
FT   VARIANT     631    631       A -> V (in NM; dbSNP:rs62541771).
FT                                {ECO:0000269|PubMed:12177386,
FT                                ECO:0000269|PubMed:12473753,
FT                                ECO:0000269|PubMed:12473769,
FT                                ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017963.
FT   VARIANT     675    675       Y -> H (in NM).
FT                                {ECO:0000269|PubMed:12409274}.
FT                                /FTId=VAR_017964.
FT   VARIANT     696    696       V -> M (in NM; dbSNP:rs121908627).
FT                                {ECO:0000269|PubMed:11528398,
FT                                ECO:0000269|PubMed:12409274,
FT                                ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017965.
FT   VARIANT     712    712       M -> T (in NM; dbSNP:rs28937594).
FT                                {ECO:0000269|PubMed:11528398,
FT                                ECO:0000269|PubMed:12409274,
FT                                ECO:0000269|PubMed:12473780,
FT                                ECO:0000269|PubMed:12497639}.
FT                                /FTId=VAR_017966.
FT   CONFLICT    338    338       D -> G (in Ref. 6; BAH12108).
FT                                {ECO:0000305}.
FT   CONFLICT    359    359       K -> R (in Ref. 6; BAH12414).
FT                                {ECO:0000305}.
FT   CONFLICT    364    364       G -> V (in Ref. 6; BAH12108).
FT                                {ECO:0000305}.
FT   CONFLICT    382    382       P -> L (in Ref. 6; BAH12108).
FT                                {ECO:0000305}.
FT   CONFLICT    498    498       V -> A (in Ref. 6; BAH12108).
FT                                {ECO:0000305}.
FT   CONFLICT    521    521       A -> V (in Ref. 6; BAH12414).
FT                                {ECO:0000305}.
FT   STRAND       10     16       {ECO:0000244|PDB:4ZHT}.
FT   HELIX        19     33       {ECO:0000244|PDB:4ZHT}.
FT   TURN         36     38       {ECO:0000244|PDB:4ZHT}.
FT   STRAND       39     46       {ECO:0000244|PDB:4ZHT}.
FT   HELIX        47     50       {ECO:0000244|PDB:4ZHT}.
FT   HELIX        52     54       {ECO:0000244|PDB:4ZHT}.
FT   HELIX        58     63       {ECO:0000244|PDB:4ZHT}.
FT   STRAND       68     72       {ECO:0000244|PDB:4ZHT}.
FT   STRAND       77     80       {ECO:0000244|PDB:4ZHT}.
FT   HELIX        81    102       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      105    113       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       114    125       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      129    134       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       142    153       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      155    161       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       162    170       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       175    177       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      178    180       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       185    189       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       197    205       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      215    218       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       223    225       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       226    243       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      247    250       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       258    267       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       270    272       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      276    280       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       284    292       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      295    299       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       302    306       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       308    311       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      315    320       {ECO:0000244|PDB:4ZHT}.
FT   TURN        321    324       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      331    335       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       340    350       {ECO:0000244|PDB:4ZHT}.
FT   HELIX       366    376       {ECO:0000244|PDB:4ZHT}.
FT   STRAND      406    414       {ECO:0000244|PDB:2YHW}.
FT   STRAND      416    425       {ECO:0000244|PDB:2YHW}.
FT   STRAND      430    437       {ECO:0000244|PDB:2YHW}.
FT   HELIX       442    462       {ECO:0000244|PDB:2YHW}.
FT   STRAND      465    479       {ECO:0000244|PDB:2YHW}.
FT   TURN        480    483       {ECO:0000244|PDB:2YHW}.
FT   STRAND      484    487       {ECO:0000244|PDB:2YHW}.
FT   STRAND      492    494       {ECO:0000244|PDB:2YHW}.
FT   STRAND      496    499       {ECO:0000244|PDB:2YHW}.
FT   HELIX       501    508       {ECO:0000244|PDB:2YHW}.
FT   STRAND      512    516       {ECO:0000244|PDB:2YHW}.
FT   HELIX       517    527       {ECO:0000244|PDB:2YHW}.
FT   TURN        530    533       {ECO:0000244|PDB:2YHW}.
FT   STRAND      537    552       {ECO:0000244|PDB:2YHW}.
FT   HELIX       567    569       {ECO:0000244|PDB:2YHW}.
FT   STRAND      571    574       {ECO:0000244|PDB:2YHW}.
FT   STRAND      584    586       {ECO:0000244|PDB:2YHW}.
FT   HELIX       587    591       {ECO:0000244|PDB:2YHW}.
FT   HELIX       593    605       {ECO:0000244|PDB:2YHW}.
FT   HELIX       624    632       {ECO:0000244|PDB:2YHW}.
FT   HELIX       636    659       {ECO:0000244|PDB:2YHW}.
FT   STRAND      663    669       {ECO:0000244|PDB:2YHW}.
FT   HELIX       672    686       {ECO:0000244|PDB:2YHW}.
FT   HELIX       689    691       {ECO:0000244|PDB:2YHW}.
FT   STRAND      695    698       {ECO:0000244|PDB:2YHW}.
FT   HELIX       704    716       {ECO:0000244|PDB:2YHW}.
SQ   SEQUENCE   722 AA;  79275 MW;  4D7D049B06B00077 CRC64;
     MEKNGNNRKL RVCVATCNRA DYSKLAPIMF GIKTEPEFFE LDVVVLGSHL IDDYGNTYRM
     IEQDDFDINT RLHTIVRGED EAAMVESVGL ALVKLPDVLN RLKPDIMIVH GDRFDALALA
     TSAALMNIRI LHIEGGEVSG TIDDSIRHAI TKLAHYHVCC TRSAEQHLIS MCEDHDRILL
     AGCPSYDKLL SAKNKDYMSI IRMWLGDDVK SKDYIVALQH PVTTDIKHSI KMFELTLDAL
     ISFNKRTLVL FPNIDAGSKE MVRVMRKKGI EHHPNFRAVK HVPFDQFIQL VAHAGCMIGN
     SSCGVREVGA FGTPVINLGT RQIGRETGEN VLHVRDADTQ DKILQALHLQ FGKQYPCSKI
     YGDGNAVPRI LKFLKSIDLQ EPLQKKFCFP PVKENISQDI DHILETLSAL AVDLGGTNLR
     VAIVSMKGEI VKKYTQFNPK TYEERINLIL QMCVEAAAEA VKLNCRILGV GISTGGRVNP
     REGIVLHSTK LIQEWNSVDL RTPLSDTLHL PVWVDNDGNC AALAERKFGQ GKGLENFVTL
     ITGTGIGGGI IHQHELIHGS SFCAAELGHL VVSLDGPDCS CGSHGCIEAY ASGMALQREA
     KKLHDEDLLL VEGMSVPKDE AVGALHLIQA AKLGNAKAQS ILRTAGTALG LGVVNILHTM
     NPSLVILSGV LASHYIHIVK DVIRQQALSS VQDVDVVVSD LVDPALLGAA SMVLDYTTRR
     IY
//
